Investors

Press Releases

Press Releases

Date Title View
Toggle Summary Liquidia and GSK Restructure Collaboration Agreement
RESEARCH TRIANGLE PARK, N.C. , June 26, 2019 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (Nasdaq: LQDA) (“Liquidia” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development and commercialization of human therapeutics using its proprietary PRINT® technology,
View HTML
Toggle Summary Liquidia Announces Clinical Update on INSPIRE; Targeting NDA Filing for LIQ861 in Late 2019
RESEARCH TRIANGLE PARK, N.C. , June 05, 2019 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (Nasdaq: LQDA) (“Liquidia”), a late-stage clinical biopharmaceutical company, today provided an update on the Phase 3 INSPIRE trial and development of LIQ861 for the treatment of pulmonary arterial
View HTML
Toggle Summary Liquidia Announces FDA Acceptance of New Drug Application for LIQ861 (treprostinil) Inhalation Powder for the Treatment of Pulmonary Arterial Hypertension
RESEARCH TRIANGLE PARK, N.C. , April 08, 2020 (GLOBE NEWSWIRE) -- Liquidia Technologies , Inc. (Nasdaq: LQDA), a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel products utilizing its proprietary PRINT ® technology, today announced that the
View HTML
Toggle Summary Liquidia Announces Poster Presentation at the 14th Annual World Congress of the Pulmonary Vascular Research Institute (PVRI)
RESEARCH TRIANGLE PARK, N.C. , Jan. 24, 2020 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (Nasdaq:LQDA) (“Liquidia”), a late-stage clinical biopharmaceutical company focused on the development and commercialization of therapeutics using its proprietary PRINT® technology, today announced that
View HTML
Toggle Summary Liquidia Announces Poster Presentation at the American Thoracic Society (ATS) International Conference 2019
To include highlights of the safety and tolerability of LIQ861 at two months of treatment in the INSPIRE Phase 3 Trial RESEARCH TRIANGLE PARK, N.C. , May 14, 2019 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (Nasdaq: LQDA) (“Liquidia”), a late-stage clinical biopharmaceutical company, today
View HTML
Toggle Summary Liquidia Appoints Seasoned Biopharmaceutical Industry Executive Dr. Richard Katz as Chief Financial Officer
RESEARCH TRIANGLE PARK, N.C. , May 22, 2019 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (Nasdaq: LQDA) (“Liquidia”), a late-stage clinical biopharmaceutical company, today announced the appointment of Richard D. Katz , M.D., as Chief Financial Officer (CFO). Dr.
View HTML
Toggle Summary Liquidia Appoints Tushar Shah, M.D., as Chief Medical Officer
RESEARCH TRIANGLE PARK, N.C. , May 18, 2020 (GLOBE NEWSWIRE) -- Liquidia Technologies , Inc. (Nasdaq: LQDA), a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel products utilizing its proprietary PRINT ® technology, today announced the
View HTML
Toggle Summary Liquidia Initiates Phase 3 Clinical Trial of LIQ861 in Patients with Pulmonary Arterial Hypertension View HTML
Toggle Summary Liquidia Presents Positive LIQ861 Results at the Annual World Congress of the Pulmonary Vascular Research Institute View HTML
Toggle Summary Liquidia Releases Final LIQ861 Results from Pivotal Phase 3 INSPIRE Study in Patients with Pulmonary Arterial Hypertension
RESEARCH TRIANGLE PARK, N.C. , April 30, 2020 (GLOBE NEWSWIRE) -- Liquidia Technologies , Inc. (Nasdaq: LQDA), a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel products utilizing its proprietary PRINT® technology, today announced that it has
View HTML